Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction (AMR-1)
Myocardial Infarction, Coronary Artery Disease
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring myocardial infarction, bone marrow, cd34+, stem cells
Eligibility Criteria
Inclusion Criteria: Age 18 - 75 years. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation > 1mm in limb leads or 2 mm in two or more precordial leads and increased levels of troponin, CPK MB or both) NYHA heart failure class of I, II or III Exclusion Criteria: Patients who are not candidates for percutaneous intervention, conscious sedation, MRI, SPECT imaging or mini-bone marrow harvest History of sustained chest pain unrelieved by nitrates, occurring 4 or more days before revascularization. Patients who fail to re-perfuse the infarct related coronary artery or have successful stent placement
Sites / Locations
- Emory University
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control Group
Treatment Group
A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.